Vestronidase alfa

Drug Profile

Vestronidase alfa

Alternative Names: Recombinant beta-glucuronidase - Ultragenyx; Recombinant human beta glucuronidase; rhGUS; UX-003

Latest Information Update: 25 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Saint Louis University
  • Developer Ultragenyx Pharmaceutical
  • Class Glucuronidases
  • Mechanism of Action Glucuronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis VII
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Mucopolysaccharidosis VII

Most Recent Events

  • 23 May 2017 Preregistration for Mucopolysaccharidosis VII (In adolescents, In children, In adults) in European Union (IV)
  • 23 May 2017 Preregistration for Mucopolysaccharidosis VII (In children, In adults, In adolescents) in USA (IV)
  • 23 May 2017 An opinion from the Committee for Medicinal Products for Human Use for vestronidase alfa indicated for Mucopolysaccharidosis VII is expected in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top